Wellgistics Health Partners with Kare PharmTech for Chronic Care Pilot
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Wellgistics Health announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management and remote patient monitoring services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently $14 Billion and expected to reach approximately $29B by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models. The pilot program currently includes multiple provider offices, with Kare Clinicals MSO serving as the billing provider on behalf of participating offices and rendering providers. The initiative is designed to support patient engagement, care coordination, and longitudinal monitoring programs through scalable operational and technology-enabled workflows. All CCM and RPM services are expected to be furnished and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, reimbursement requirements, and payor program rules.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGRX
About WGRX
Wellgistics Health, Inc. is a holding company, which conducts business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It focuses on specialty medications and a community-based model offering home delivery services to patients. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows for clinical services to be connected to the Company’s health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, improve prescription price transparency, and provide additional concierge services. Its products include Kyzatrex and Semaglutide and Tirzepatide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wellgistics Announces 1-for-50 Reverse Stock Split
- Reverse Split Announcement: Wellgistics Health, Inc. will implement a 1-for-50 reverse stock split on May 26, 2026, aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing compliance.
- Shareholder Approval: The reverse split plan was approved by a majority of shareholders on April 2, 2026, and is expected to reduce the outstanding shares from approximately 126.7 million to about 2.5 million, significantly decreasing the market float.
- No Action Required for Shareholders: Shareholders holding shares in electronic book-entry form will not need to take any action, as their holdings will be automatically adjusted, simplifying the process and reducing operational complexity for investors.
- Future Growth Strategy: The reverse split aligns with Wellgistics' strategy of integrating its AI platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™, aiming to enhance its competitive position in the health information technology sector.
See More
Wellgistics Health Approves 1-for-50 Reverse Stock Split
- Reverse Stock Split Plan: Wellgistics Health is set to implement a 1-for-50 reverse stock split on May 26, 2026, aimed at increasing the per-share trading price to comply with Nasdaq's minimum bid requirements, thereby enhancing the company's market compliance.
- Share Impact: The reverse split will reduce outstanding shares from approximately 125.7 million to 2.5 million, while the total authorized shares remain unchanged; proportional adjustments will be made to outstanding options, warrants, and convertible securities to protect investor interests.
- Market Performance Review: WGRX shares have traded between $0.07 and $2.56 over the past year, closing at $0.12, down 23.12%, and further declining 24.65% in pre-market trading, indicating a negative market reaction to the split announcement.
- Company Background: Wellgistics integrates its proprietary AI platform EinsteinRx with its blockchain-enabled PharmacyChain system to optimize prescription drug dispensing, connecting over 6,500 pharmacies and 200 manufacturers, showcasing its innovative capabilities in the health information technology sector.
See More
Wellgistics Health Announces 1-for-50 Reverse Stock Split
- Reverse Stock Split Plan: Wellgistics Health has announced a 1-for-50 reverse stock split effective May 26, 2026, aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing on the exchange.
- Shareholder Approval: The plan received formal approval from the company's Board of Directors and a majority of voting stockholders on April 2, 2026, reflecting shareholder support and confidence in the company's strategic adjustments.
- Impact on Shares: Following the reverse split, the number of outstanding shares will decrease from approximately 125.67 million to around 2.51 million, while the authorized share capital remains unchanged, ensuring proportional adjustments for all shareholders.
- Automatic Adjustment Mechanism: Shareholders holding shares in book-entry form will not need to take any action, as adjustments will also be made automatically for those with shares through brokers or nominees, ensuring that shareholder rights are preserved post-split.
See More
Formation of DelivMeds AI with Approximate Asset Value of $4 Billion
- Asset Value: The formation of DelivMeds AI is expected to have an approximate asset value of $4 billion, stemming from a comprehensive partnership between Datavault AI and Wellgistics Health aimed at enhancing healthcare service efficiency through blockchain and AI integration, thereby securing a competitive edge in the rapidly evolving healthcare market.
- Technology Integration and Expansion: The fully binding term sheet signed between Datavault AI and Wellgistics Health expands the PharmacyChain™ platform to include Healthcare-as-a-Service (HaaS), connecting over 6,500 pharmacies and 200 manufacturers, significantly improving the efficiency and transparency of pharmaceutical delivery.
- Innovative Healthcare Solutions: Following the acquisition of the QOLPOM patent portfolio, DelivMeds AI will leverage biometric verification and AI-driven drones to enhance pharmaceutical delivery and sample collection in rural areas, which is expected to greatly improve accessibility and compliance in healthcare services.
- Market Promotion and Collaboration: The
See More
Wellgistics Health Reports Q1 Loss and $105M Acquisition Intent
- Q1 Loss: Wellgistics Health reported a GAAP EPS of -$0.07 for Q1, indicating challenges in profitability that may affect investor confidence and lead to stock price volatility.
- Acquisition Intent: The company has signed a Letter of Intent to explore a $105 million acquisition of Neuritek, aiming to enhance its competitiveness by expanding its product line and market share.
- Strategic Implications: If successful, this acquisition could allow Wellgistics Health to enter new market segments, strengthening its position in the health technology sector and laying the groundwork for future growth.
- Market Reaction: While the Q1 loss may negatively impact stock prices, the announcement of the acquisition intent could attract investor interest, enhancing market expectations for the company's long-term development.
See More
iSpecimen Shares Surge 69% on New Shipping Model Announcement
- Shipping Model Innovation: iSpecimen's announcement of a new shipping model that reduces biospecimen transit times by up to 85% led to a more than 69% surge in its stock price during Friday's pre-market session, indicating strong market confidence in its operational efficiency.
- Share Settlement Termination: Wellgistics' stock rose nearly 45% in pre-market trading after the company announced the termination of its share settlement agreement with Silverback Capital, potentially paving the way for future capital structure adjustments.
- Successful Fundraising: Erayak Power raised $400,000 from the sale of common stock to investors, resulting in a 34% pre-market stock increase, despite its year-to-date decline of 88%, reflecting market recognition of its fundraising capabilities.
- Cautious Market Sentiment: Despite strong performances from individual stocks, the overall U.S. equities edged lower in pre-market trading due to lingering tensions from a fragile ceasefire between the U.S. and Iran, highlighting investor caution in the current climate.
See More
Wellgistics Announces 1-for-50 Reverse Stock Split
- Reverse Split Announcement: Wellgistics Health, Inc. will implement a 1-for-50 reverse stock split on May 26, 2026, aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing compliance.
- Shareholder Approval: The reverse split plan was approved by a majority of shareholders on April 2, 2026, and is expected to reduce the outstanding shares from approximately 126.7 million to about 2.5 million, significantly decreasing the market float.
- No Action Required for Shareholders: Shareholders holding shares in electronic book-entry form will not need to take any action, as their holdings will be automatically adjusted, simplifying the process and reducing operational complexity for investors.
- Future Growth Strategy: The reverse split aligns with Wellgistics' strategy of integrating its AI platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™, aiming to enhance its competitive position in the health information technology sector.
See More
Wellgistics Health Approves 1-for-50 Reverse Stock Split
- Reverse Stock Split Plan: Wellgistics Health is set to implement a 1-for-50 reverse stock split on May 26, 2026, aimed at increasing the per-share trading price to comply with Nasdaq's minimum bid requirements, thereby enhancing the company's market compliance.
- Share Impact: The reverse split will reduce outstanding shares from approximately 125.7 million to 2.5 million, while the total authorized shares remain unchanged; proportional adjustments will be made to outstanding options, warrants, and convertible securities to protect investor interests.
- Market Performance Review: WGRX shares have traded between $0.07 and $2.56 over the past year, closing at $0.12, down 23.12%, and further declining 24.65% in pre-market trading, indicating a negative market reaction to the split announcement.
- Company Background: Wellgistics integrates its proprietary AI platform EinsteinRx with its blockchain-enabled PharmacyChain system to optimize prescription drug dispensing, connecting over 6,500 pharmacies and 200 manufacturers, showcasing its innovative capabilities in the health information technology sector.
See More
Wellgistics Health Announces 1-for-50 Reverse Stock Split
- Reverse Stock Split Plan: Wellgistics Health has announced a 1-for-50 reverse stock split effective May 26, 2026, aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing on the exchange.
- Shareholder Approval: The plan received formal approval from the company's Board of Directors and a majority of voting stockholders on April 2, 2026, reflecting shareholder support and confidence in the company's strategic adjustments.
- Impact on Shares: Following the reverse split, the number of outstanding shares will decrease from approximately 125.67 million to around 2.51 million, while the authorized share capital remains unchanged, ensuring proportional adjustments for all shareholders.
- Automatic Adjustment Mechanism: Shareholders holding shares in book-entry form will not need to take any action, as adjustments will also be made automatically for those with shares through brokers or nominees, ensuring that shareholder rights are preserved post-split.
See More
Formation of DelivMeds AI with Approximate Asset Value of $4 Billion
- Asset Value: The formation of DelivMeds AI is expected to have an approximate asset value of $4 billion, stemming from a comprehensive partnership between Datavault AI and Wellgistics Health aimed at enhancing healthcare service efficiency through blockchain and AI integration, thereby securing a competitive edge in the rapidly evolving healthcare market.
- Technology Integration and Expansion: The fully binding term sheet signed between Datavault AI and Wellgistics Health expands the PharmacyChain™ platform to include Healthcare-as-a-Service (HaaS), connecting over 6,500 pharmacies and 200 manufacturers, significantly improving the efficiency and transparency of pharmaceutical delivery.
- Innovative Healthcare Solutions: Following the acquisition of the QOLPOM patent portfolio, DelivMeds AI will leverage biometric verification and AI-driven drones to enhance pharmaceutical delivery and sample collection in rural areas, which is expected to greatly improve accessibility and compliance in healthcare services.
- Market Promotion and Collaboration: The
See More
Wellgistics Health Reports Q1 Loss and $105M Acquisition Intent
- Q1 Loss: Wellgistics Health reported a GAAP EPS of -$0.07 for Q1, indicating challenges in profitability that may affect investor confidence and lead to stock price volatility.
- Acquisition Intent: The company has signed a Letter of Intent to explore a $105 million acquisition of Neuritek, aiming to enhance its competitiveness by expanding its product line and market share.
- Strategic Implications: If successful, this acquisition could allow Wellgistics Health to enter new market segments, strengthening its position in the health technology sector and laying the groundwork for future growth.
- Market Reaction: While the Q1 loss may negatively impact stock prices, the announcement of the acquisition intent could attract investor interest, enhancing market expectations for the company's long-term development.
See More
iSpecimen Shares Surge 69% on New Shipping Model Announcement
- Shipping Model Innovation: iSpecimen's announcement of a new shipping model that reduces biospecimen transit times by up to 85% led to a more than 69% surge in its stock price during Friday's pre-market session, indicating strong market confidence in its operational efficiency.
- Share Settlement Termination: Wellgistics' stock rose nearly 45% in pre-market trading after the company announced the termination of its share settlement agreement with Silverback Capital, potentially paving the way for future capital structure adjustments.
- Successful Fundraising: Erayak Power raised $400,000 from the sale of common stock to investors, resulting in a 34% pre-market stock increase, despite its year-to-date decline of 88%, reflecting market recognition of its fundraising capabilities.
- Cautious Market Sentiment: Despite strong performances from individual stocks, the overall U.S. equities edged lower in pre-market trading due to lingering tensions from a fragile ceasefire between the U.S. and Iran, highlighting investor caution in the current climate.
See More
